
VVOS Valuation
Vivos Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
VVOS Relative Valuation
VVOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VVOS is overvalued; if below, it's undervalued.
Historical Valuation
Vivos Therapeutics Inc (VVOS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.21 is considered Undervalued compared with the five-year average of -2.76. The fair price of Vivos Therapeutics Inc (VVOS) is between 6.75 to 8.53 according to relative valuation methord. Compared to the current price of 5.82 USD , Vivos Therapeutics Inc is Undervalued By 13.79%.
Relative Value
Fair Zone
6.75-8.53
Current Price:5.82
13.79%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
7.78
P/B
Median3y
23.95
Median5y
16.79
-43.00
FCF Yield
Median3y
-135.53
Median5y
-96.15
Competitors Valuation Multiple
The average P/S ratio for VVOS's competitors is 9.12, providing a benchmark for relative valuation. Vivos Therapeutics Inc Corp (VVOS) exhibits a P/S ratio of 2.21, which is -75.80% above the industry average. Given its robust revenue growth of -11.79%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch

RENT
Rent the Runway Inc
4.980
USD
+2.89%

TRSG
Tungray Technologies Inc
1.583
USD
-1.98%

CLPS
CLPS Inc
0.995
USD
-0.50%

FEAM
5E Advanced Materials Inc
3.580
USD
+3.17%

AIFF
Firefly Neuroscience Inc
3.030
USD
+0.66%

XBP
XBP Europe Holdings Inc
0.914
USD
-2.77%

CXAI
CXApp Inc
1.020
USD
-1.92%

GROW
US Global Investors Inc
2.470
USD
0.00%

LEXX
Lexaria Bioscience Corp
0.946
USD
+8.74%

VSTE
Vast Renewables Ltd
0
USD
-23.48%
FAQ

Is Vivos Therapeutics Inc (VVOS) currently overvalued or undervalued?
Vivos Therapeutics Inc (VVOS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.21 is considered Undervalued compared with the five-year average of -2.76. The fair price of Vivos Therapeutics Inc (VVOS) is between 6.75 to 8.53 according to relative valuation methord. Compared to the current price of 5.82 USD , Vivos Therapeutics Inc is Undervalued By 13.79% .

What is Vivos Therapeutics Inc (VVOS) fair value?

How does VVOS's valuation metrics compare to the industry average?

What is the current P/B ratio for Vivos Therapeutics Inc (VVOS) as of Jul 20 2025?

What is the current FCF Yield for Vivos Therapeutics Inc (VVOS) as of Jul 20 2025?

What is the current Forward P/E ratio for Vivos Therapeutics Inc (VVOS) as of Jul 20 2025?
